<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277132</url>
  </required_header>
  <id_info>
    <org_study_id>80-83600-98-20081</org_study_id>
    <nct_id>NCT02277132</nct_id>
  </id_info>
  <brief_title>The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)</brief_title>
  <acronym>STRIDER</acronym>
  <official_title>The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Severe, early-onset fetal growth restriction (FGR) due to placental insufficiency
      is associated with a high risk of perinatal morbidity with long-lasting sequelae and
      mortality. Placental insufficiency is the result of abnormal formation and function of the
      placenta (placentation) with inadequate remodelling of the maternal spiral (uteroplacental)
      arteries. There is currently no therapy available with demonstrated effectiveness. Evidence
      suggests Sildenafil citrate improves uteroplacental blood flow, growth, and meaningful
      outcomes.

      Objective: To evaluate the effectiveness of sildenafil (versus placebo) in achieving healthy
      perinatal survival.

      Study design: Multicenter nationwide randomized placebo-controlled clinical trial.

      Study population: Women with a singleton pregnancy between 20 and 30 weeks with severe fetal
      growth restriction of likely placental origin, and with estimated significant likelihood of
      perinatal death.

      Intervention: Sildenafil 25mg or placebo tablet orally three times daily. Main study
      parameters/endpoints: Perinatal healthy survival, i.e. survival without severe neonatal
      morbidity at term age.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Taking tablets three times daily. No additional ultrasounds, other than standard
      clinical protocol, one extra blood sample at inclusion. No risks anticipated, unexpected
      medication-associated risks can't be excluded on beforehand.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intact neonatal survival until term age</measure>
    <time_frame>Term age, up to 20 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal growth velocity assessed by ultrasound: abdominal circumference measurements (AC)</measure>
    <time_frame>At contact moments with the patient, up to 20 weeks after randomization</time_frame>
    <description>Average daily increase in ultrasound-estimated AC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age-adequate performance on the two-year Bayley scales of infant development (BSID)-III (composite cognitive score and composite motor score)</measure>
    <time_frame>2 years corrected age, up to 2 years and three months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-incidence and severity of the maternal syndrome of pre-eclampsia / HELLP-syndrome (Hemolysis Elevated Liver enzymes Low Platelets)</measure>
    <time_frame>At contact moments with the patient, up to 20 weeks after randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Fetal ultrasound and Doppler studies: estimated fetal weight, abdominal circumference and Doppler of umbilical artery</measure>
    <time_frame>At contact moments with the patients, up to 20 weeks after randomization</time_frame>
    <description>Umbilical artery, middle cerebral artery, ductus venosus and aortic isthmus Doppler indices; fetal biometry; amniotic fluid index; deepest vertical amniotic fluid pocket.</description>
  </other_outcome>
  <other_outcome>
    <measure>PlGF (Placental Growth Factor) point-of-care assessment</measure>
    <time_frame>At baseline</time_frame>
    <description>If possible in designated clinic</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Fetal Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 25 mg tablets three times daily orally from randomization until delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets three times daily orally from randomization until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 25 mg three times daily orally from randomization until delivery</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets three times daily orally from randomization until delivery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria ((I OR II) AND III):

          -  At 20+0-27+6 weeks: an ultrasound measurement of the fetal abdominal circumference
             (AC) &lt;3rd percentile for gestational age or an ultrasound estimate of fetal weight
             (EFW) &lt;5th percentile OR

          -  At 28+0-29+6 weeks: an ultrasound estimate of fetal weight (EFW) &lt;700 grams using
             Hadlock C formula AND

          -  Likely placental origin defined by (a AND/OR b AND/OR c AND/OR d)

               -  The presence of uterine artery notching

               -  Abnormal flow velocity patterns of the umbilical artery or middle cerebral artery

               -  Maternal hypertensive disorders

               -  Low PlGF in point-of-care assessment

        Exclusion Criteria:

          -  Plan to terminate pregnancy for maternal or fetal indication within days

          -  Known multiple pregnancy

          -  Identified congenital anomalies or congenital infection

          -  Maternal age at eligibility &lt;18 years

          -  Cocaine use

          -  Current use of sildenafil

          -  Current use of cyp3A5 inhibitors: amiodaron, azitromycine, ciclosporine,
             claritromycine, diltiazem, erytromycine, fluconazol, itraconazol, ketoconazol,
             verapamil, voriconazol.

          -  Recent myocardial infarction or stroke
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.W. Ganzevoort, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K Bloemenkamp, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P von Dadelszen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C de Groot, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>VU Medisch Centrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M.W. de Laat, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B.W. Mol, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Porath, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Perinataal Centrum MMC Veldhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.A.M. van der Post, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. van Wassenaer, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J.W. Ganzevoort, MD PhD</last_name>
    <phone>0031205663454</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>J.A.M. van der Post, MD PhD</last_name>
    <phone>0031205663454</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud Medisch Centrum Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Van Drongelen</last_name>
      <phone>0031243611111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Al-Nasiry</last_name>
      <phone>0031433876543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord Brabant</state>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J van Laar</last_name>
      <phone>003140888 80 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Bax</last_name>
      <phone>0031204444444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wessel Ganzevoort, MD PhD</last_name>
      <phone>0031205663769</phone>
      <email>j.w.ganzevoort@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Wessel Ganzevoort, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J van Eyck</last_name>
      <phone>0031384245000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Sueters</last_name>
      <phone>0031715269111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JJ Duvekot</last_name>
      <phone>0031107040704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Elvan-Taspinar</last_name>
      <phone>0031503616161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JB Derks</last_name>
      <phone>0031887555555</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Wessel Ganzevoort</investigator_full_name>
    <investigator_title>J.W. Ganzevoort MD PhD</investigator_title>
  </responsible_party>
  <keyword>Fetal growth restriction</keyword>
  <keyword>Sildenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

